Dr Bernadett Szabados (University College London Hospital, London, UK), Dr Alexandra Masson-Lecomte (Hôpital Henri Mondor, Créteil, France), Dr Giuseppe Simone (Regina Elena National Cancer Institute, Rome, Italy), Dr Félix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain) discuss recent advancements in non-muscle invasive bladder cancer treatment, focusing on FGFR alterations and personalised care.

They highlight new intravesical devices for better drug delivery and compare chemotherapy options, including BCG and gemcitabine.

Updates on BCG treatment guidelines and emerging treatments are shared, along with innovations in follow-up care like urinary biomarker tests.

The importance of bladder-sparing approaches and precision medicine in future research is also emphasised.